We are live on ! Find out more
GRCL

Gracell Biotechnologies Inc. American Depositary Shares

Delisted

GRCL was delisted on the 21st of February, 2024.

32 hedge funds and large institutions have $176M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

134% more capital invested

Capital invested by funds: $75.1M → $176M (+$101M)

6% less funds holding

Funds holding: 3432 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
32
Holders Change
-2
Holders Change %
-5.88%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
6
Reduced
10
Closed
8
Calls
Puts
Net Calls
Net Calls Change

GRCL Hedge Fund Activity: Q2 2022 in Review

32 of the 5,791 institutional investors tracked by Wall St. Rank reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q2 2022, worth a combined $176M — up 134% from $75.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GRCL and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Capital International Inc, adding an estimated $2.05M. The largest seller was Wellington Management Group, cutting an estimated $2.33M.

  • 32 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q2 2022, down from 34 in Q1 2022.
  • Funds reported $176M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q2 2022, up 134% quarter-over-quarter.
  • 6 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q2 2022 and 8 closed out, a net change of -2 holders.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q2 2022 was Capital International Inc, an estimated $2.05M added.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q2 2022 was Wellington Management Group, an estimated $2.33M sold.

Based on aggregated 13F filings for Q2 2022.